Nuwellis Inc (NUWE) - News Archive

Nuwellis, Inc.: Leadership Transition Amidst Financial Growth and Strategic Vision for the FutureIn a transformative period for Nuwellis, Inc. a key player in the medical technology industry, the company recently announ...

On November 5, 2024, Minneapolis-based Nuwellis, Inc. (Nasdaq: NUWE), a prominent player in the medical technology sector, notably specializing in solutions for fluid overload, announced a significant financial mileston...

In a move destined to reshape its financial outlook, Nuwellis Inc. announced a staggering 397% daily increase in the reimbursement rate for its Aquadex SmartFlow Therapy, effective January 1, 2025, from the Centers for...

In a recent press release, medical technology company Nuwellis, Inc. (Nasdaq: NUWE) has revealed its entry into a definitive securities purchase agreement with select institutional investors. Under this agreement, Nuwel...

MINNEAPOLIS, Aug. 08, 2024 - Nuwellis, Inc. (Nasdaq: NUWE), a prominent medical technology company dedicated to revolutionizing the lives of individuals suffering from fluid overload, excitedly announced today that The...

A recent groundbreaking medical milestone has been achieved in pediatric care with the first commercial use of SeaStar Medical s QUELIMMUNE therapy, administered at Cincinnati Children s Hospital. This innovative treatm...

Nuwellis Announces Pricing of $2.0 Million Offering to Fuel Growth in Fluid Overload Treatment SectorMINNEAPOLIS, July 24, 2024 - Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the l...

In the ever-evolving landscape of medical technology, advancements that significantly impact patient outcomes are celebrated as monumental achievements. Nuwellis, Inc. (Nasdaq: NUWE), a company renowned for its dedicati...

Nuwellis, Inc., a renowned medical technology company focused on revolutionizing the lives of individuals suffering from fluid overload, made a significant announcement on June 26, 2024. The company revealed its plans f...

Nuwellis Advances Medical Technology with New Pediatric Renal Therapy Patent and Expanded Applications for Fluid Overload Treatment MINNEAPOLIS, June 25, 2024 Nuwellis, Inc. (Nasdaq: NUWE), a pioneering medical technolo...

In a landmark move, medical technology company Nuwellis Inc. has announced an extension of its supply and collaboration agreement with DaVita, marking an important milestone in the pilot collaboration for Aquadex Ultraf...

Nuwellis, a leading medical technology company dedicated to improving the lives of people suffering from fluid overload, has recently announced the expansion of its ultrafiltration program to include pediatric patients...

MINNEAPOLIS, May 09, 2024 - Nuwellis, Inc. (Nasdaq: NUWE), a leading medical technology company specializing in fluid overload treatment, has recently finalized a purchase agreement with one of the top 25 largest integr...

Nuwellis Announces Successful Completion of $2.7 Million Public OfferingMinneapolis-based medical technology company Nuwellis, Inc. (Nasdaq: NUWE) has recently concluded its highly anticipated public offering, securing...

Nuwellis, Inc., a medical technology company specializing in treating fluid overload, has recently announced the successful pricing of its public offering, raising $2.7 million for the company. This article will outline...

Heart failure continues to be a major global health burden, affecting millions of individuals and causing substantial morbidity and mortality. The management of heart failure patients has relied heavily on the use of in...

MINNEAPOLIS, Feb. 20, 2024 - Nuwellis, Inc. (Nasdaq: NUWE) disclosed today that it has sanctioned equity awards for two new employees under its 2021 Inducement Plan. The company s independent directors greenlit these aw...

Nuwellis, a pioneering medical technology company, is set to unveil groundbreaking clinical data and host a satellite symposium at the upcoming Technology and Heart Failure Therapeutics Conference. The company will shar...

End-stage liver disease patients often encounter complications primarily due to fluid overload, which is a largely unavoidable symptom. Currently, diuretics are used to facilitate the removal of this excess fluid in the...

Nuwellis, Inc., a company dedicated to improving the lives of individuals suffering from fluid overload, recently released new real-world data highlighting the clinical benefits of using ultrafiltration therapy with hem...